Dexmedetomidine HCl - Moligand™, 10mM in DMSO , Adrenergic receptor alpha-2 agonist, CAS No.145108-58-3, Adrenergic receptor alpha-2 agonist

CAS: 145108-58-3 Cat. No.: D409289 Formula: C₁₃H₁₆N₂·HCl Peso molecolare: 236.74 Numero EC: 682-047-2

GRADE & PURITY Moligand™, 10mM in DMSO

Synonyms

5-​[(1S)​-​1-​(2,​3-​dimethylphenyl)​ethyl]​-​1H-​imidazole,hydrochloride (1:1)

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

Panoramica

Information

Dexmedetomidine HCl is a highly selective and potent alpha-2 adrenoceptor agonist, which reduces anesthetic requirements for patients by providing significant sedation.
In vitro

In vivo

Cell Data

cell lines：

Concentrations：

Incubation Time：

Powder Purity:≥99%

Specifications

Sinonimi

5-​[(1S)​-​1-​(2,​3-​dimethylphenyl)​ethyl]​-​1H-​imidazole,hydrochloride (1:1)

Specifiche e purezza

Moligand™, 10mM in DMSO

Meccanismi biochimici e fisiologici

Dexmedetomidine HCl is a highly selective and potent alpha-2 adrenoceptor agonist, which reduces anesthetic requirements for patients by providing significant sedation.

Condizioni di conservazione di stoccaggio

Store at -80°C

Spedito in

Dry ice packs + Cold packs

Questo prodotto richiede spedizione a catena fredda. I servizi di terra e altri servizi economici non sono disponibili.

Grado

Moligand™

Tipo di azione

AGONIST

Meccanismo d'azione

Adrenergic receptor alpha-2 agonist

Nomi e identificatori

• Isomeri SMILES: CC1=C(C(=CC=C1)[C@H](C)C2=CN=CN2)C.Cl
• WGK Germania: 3
• RTECS: NI5156750
• Peso molecolare: 236.74
• Reaxy-Rn: 5362300
• Reaxys-RN_link_address: https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=5362300&ln=

Proprietà chimiche e fisiche

• Solubilità: Solubility (25°C) In vitro Water: 34 mg/mL (198.65 mM); DMSO: 7 mg/mL (40.89 mM); Ethanol: Insoluble
• Rotazione specifica [α]: 51° (C=1,H2O)
• Punto di fusione (°C): 158 °C

Riferimenti

1. Kaiyu Xu, Ying Zhang, Yongxuan Chen, Xiaojia Zhu, Yu Li, Longbao Lv, Xiechao He, Zhengfei Hu, Yifan Li, Maosen Ye, Dewei Jiang, Zhanlong He, Weihua Jin, Yanyan Li, Xiaomei Yu, Deng-Feng Zhang, Karl Herrup, Ping Zheng, Yong-Gang Yao, Dong-Dong Wu, Jiali Li.  (2025)  ATM deficiency drives phenotypic diversity and Purkinje cell degeneration in a macaque model of ataxia-telangiectasia.  Cell Reports Medicine,      [PMID:40961921] [10.1016/j.xcrm.2025.102355]

2. Qiuxia Liao, Zhi Feng, Hairong Lin, Ye Zhou, Xinxin Lin, Xiao Lin, Huichang Zhuo.  (2025)  Dexmedetomidine improves septic acute kidney injury by inhibiting inflammation and oxidative stress through the activation of the Pink1/Park2 autophagy pathway.  RENAL FAILURE,      [PMID:40485166] [10.1080/0886022X.2025.2513677]

3. Ce Wu, Di Wu, LiJie Xie, HouYong Yan, Wei Zhang, Fei Yu.  (2026)  Near-Infrared Responsive Injectable Thermosensitive Hydrogel Sequentially Releases Dexmedetomidine and Ropivacaine for Postoperative Pain Management.  COLLOIDS AND SURFACES A-PHYSICOCHEMICAL AND ENGINEERING ASPECTS,      [PMID:] [10.1016/j.colsurfa.2026.139503]